Pier Giuseppe Pelicci

TTfactor SRL develops oncology research, technology advancement and intellectual property transfer programs. It operates as a technology transfer and market connection company focused on the advancement of scientific results through technology licensing, sponsored research, clinical trials, drug discovery, and molecular medicine programs. The company was founded by Daniela Bellomo in 2010 and is headquartered in Milan, Italy.

Congenia SRL operates as pharmaceutical company, is engaged in the development of novel therapeutics for diseases associated with mitochondrial stress-induced dysfunction. The company develops small molecule drugs that target the mitochondrial permeability transition pore, a protein channel with various macromolecular components that along with mitochondrial protein p66, appears to be associated with oxidative stress-induced cell death. The company was founded in 2004 by Saverio Minucci, Pier Giuseppe Pelicci, Marco Giorgio and Paolo Bernardi and is headquartered in Milan, Italy.

Fondazione Umberto Veronesi engages in the promotion of scientific research and projects for prevention, health education, and dissemination of science. Its activities include the provision of research grants for doctors and researchers, financing of projects for the development of new disease treatments, the execution of prevention and education campaigns for the adoption of healthy lifestyles, and the organization of international conferences for the future of science for well-being. The company was founded by Umberto Veronesi in 2003 and is headquartered in Milan, Italy.

Istituto Europeo di Oncologia SRL is a holding company, which operates oncology hospitals. It offers healthcare services, basic and translational cancer research, and PhD and post doctoral programs in molecular medicine. The company was founded by Umberto Veronesi on May 30, 1994 and is headquartered in Milan, Italy.